Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation
Review article, 2012
Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called - omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes.
filamentous fungi
therapeutic proteins
escherichia-coli
human hemoglobin
human serum-albumin
heterologous proteins
expression
alpha-hemoglobin
pichia-pastoris
saccharomyces-cerevisiae
systems
Author
Jose Luis Martinez Ruiz
Chalmers, Chemical and Biological Engineering, Life Sciences
Lifang Liu
Chalmers, Chemical and Biological Engineering, Life Sciences
Dina Petranovic Nielsen
Chalmers, Chemical and Biological Engineering, Life Sciences
Jens B Nielsen
Chalmers, Chemical and Biological Engineering, Life Sciences
Current Opinion in Biotechnology
0958-1669 (ISSN) 1879-0429 (eISSN)
Vol. 23 6 965-971Industrial Systems Biology of Yeast and A. oryzae (INSYSBIO)
European Commission (EC) (EC/FP7/247013), 2010-01-01 -- 2014-12-31.
Areas of Advance
Life Science Engineering (2010-2018)
Subject Categories
Chemical Sciences
DOI
10.1016/j.copbio.2012.03.011